These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22487174)

  • 1. Isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors: SAR and pharmacokinetic evaluation.
    Banerjee A; Yadav PS; Bajpai M; Sangana RR; Gullapalli S; Gudi GS; Gharat LA
    Bioorg Med Chem Lett; 2012 May; 22(9):3223-8. PubMed ID: 22487174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model.
    Banerjee A; Patil S; Pawar MY; Gullapalli S; Gupta PK; Gandhi MN; Bhateja DK; Bajpai M; Sangana RR; Gudi GS; Khairatkar-Joshi N; Gharat LA
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6286-91. PubMed ID: 22944118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation.
    Guo J; Watson A; Kempson J; Carlsen M; Barbosa J; Stebbins K; Lee D; Dodd J; Nadler SG; McKinnon M; Barrish J; Pitts WJ
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1935-8. PubMed ID: 19272774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDE7-Selective and Dual Inhibitors: Advances in Chemical and Biological Research.
    Jankowska A; Swierczek A; Chlon-Rzepa G; Pawlowski M; Wyska E
    Curr Med Chem; 2017; 24(7):673-700. PubMed ID: 28093982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unraveling phosphodiesterase surfaces. Identification of phosphodiesterase 7 allosteric modulation cavities.
    Redondo M; Soteras I; Brea J; González-García A; Cadavid MI; Loza MI; Martinez A; Gil C; Campillo NE
    Eur J Med Chem; 2013; 70():781-8. PubMed ID: 24239625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 2-(cyclopentylamino)thieno[3,2-d]pyrimidin-4(3H)-one derivatives as a new series of potent phosphodiesterase 7 inhibitors.
    Kawai K; Endo Y; Asano T; Amano S; Sawada K; Ueo N; Takahashi N; Sonoda Y; Nagai M; Kamei N; Nagata N
    J Med Chem; 2014 Dec; 57(23):9844-54. PubMed ID: 25383422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.
    Kempson J; Pitts WJ; Barbosa J; Guo J; Omotoso O; Watson A; Stebbins K; Starling GC; Dodd JH; Barrish JC; Felix R; Fischer K
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1829-33. PubMed ID: 15780616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microwave-assisted synthesis of potent PDE7 inhibitors containing a thienopyrimidin-4-amine scaffold.
    Sánchez AI; Meneses R; Mínguez JM; Núñez A; Castillo RR; Filace F; Burgos C; Vaquero JJ; Álvarez-Builla J; Cortés-Cabrera A; Gago F; Terricabras E; Segarra V
    Org Biomol Chem; 2014 Jun; 12(24):4233-42. PubMed ID: 24838636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.
    Lorthiois E; Bernardelli P; Vergne F; Oliveira C; Mafroud AK; Proust E; Heuze L; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Wrigglesworth R; Descours A; Soulard P; Berna P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4623-6. PubMed ID: 15324876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and evaluation of quinazoline derivatives as phosphodiesterase 7 inhibitors.
    Sánchez AI; Martínez-Barrasa V; Burgos C; Vaquero JJ; Alvarez-Builla J; Terricabras E; Segarra V
    Bioorg Med Chem; 2013 Apr; 21(8):2370-2378. PubMed ID: 23454131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors.
    García AM; Brea J; Morales-García JA; Perez DI; González A; Alonso-Gil S; Gracia-Rubio I; Ros-Simó C; Conde S; Cadavid MI; Loza MI; Perez-Castillo A; Valverde O; Martinez A; Gil C
    J Med Chem; 2014 Oct; 57(20):8590-607. PubMed ID: 25264825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and SAR study of 2-(4-pyridylamino)thieno[3,2-d]pyrimidin-4(3H)-ones as soluble and highly potent PDE7 inhibitors.
    Endo Y; Kawai K; Asano T; Amano S; Asanuma Y; Sawada K; Ogura K; Nagata N; Ueo N; Takahashi N; Sonoda Y; Kamei N
    Bioorg Med Chem Lett; 2015 Feb; 25(3):649-53. PubMed ID: 25529739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New methods for the discovery and synthesis of PDE7 inhibitors as new drugs for neurological and inflammatory disorders.
    Safavi M; Baeeri M; Abdollahi M
    Expert Opin Drug Discov; 2013 Jun; 8(6):733-51. PubMed ID: 23570245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-(Isopropylamino)thieno[3,2-d]pyrimidin-4(3H)-one derivatives as selective phosphodiesterase 7 inhibitors with potent in vivo efficacy.
    Endo Y; Kawai K; Asano T; Amano S; Asanuma Y; Sawada K; Onodera Y; Ueo N; Takahashi N; Sonoda Y; Kamei N; Irie T
    Bioorg Med Chem Lett; 2015 May; 25(9):1910-4. PubMed ID: 25866242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors.
    Gewald R; Rueger C; Grunwald C; Egerland U; Hoefgen N
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6652-6. PubMed ID: 21983442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase 7(PDE7): A unique drug target for central nervous system diseases.
    Chen Y; Wang H; Wang WZ; Wang D; Skaggs K; Zhang HT
    Neuropharmacology; 2021 Sep; 196():108694. PubMed ID: 34245775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5.
    Wang G; Liu Z; Chen T; Wang Z; Yang H; Zheng M; Ren J; Tian G; Yang X; Li L; Li J; Suo J; Zhang R; Jiang X; Terrett NK; Shen J; Xu Y; Jiang H
    J Med Chem; 2012 Dec; 55(23):10540-50. PubMed ID: 23137303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, Anti-inflammatory Activity and Docking Studies of Some Newer 1,3-Thiazolidine-2,4-dione Derivatives as Dual Inhibitors of PDE4 and PDE7.
    Sharma H; Lather V; Grewal AS; Pandita D
    Curr Comput Aided Drug Des; 2019; 15(3):225-234. PubMed ID: 30280674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Ducrot P; Wrigglesworth R; Berlioz-Seux F; Coleon F; Chevalier E; Moreau F; Idrissi M; Tertre A; Descours A; Berna P; Li M
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4615-21. PubMed ID: 15324875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.